This paper is the forty-fifth consecutive installment of the annual anthological review of
research concerning the endogenous opioid system, summarizing articles published during …

Introduction Medications for opioid use disorder (MOUD) include opioid agonist therapies
(OAT)(buprenorphine and methadone), and opioid antagonists (extended-release …

Substance use disorder and human immunodeficiency virus An estimated 11.1% of people
with human immunodeficiency virus (HIV)(PWH) have a diagnosis of substance use disorder …

Abstract Background In the United States, a disproportionate number of persons with HIV
(PWH) and opioid use disorder (OUD) are involved in the justice system. Medications for …

Research in these populations is challenging because of a myriad factors, including
absence of accommodations in the study structure, recruitment issues, ethical challenges …

Establishing mutual trust is paramount.• Linkage to care and retention in care require
enhanced multidisciplinary teamwork.• Long-acting injectable antipsychotics are important …

The opioid antagonist extended-release naltrexone (XR-NTX) blocks the effects of opioids
for four consecutive weeks, and is a novel approach in the treatment of opioid use disorder …

As a result of the intersection of criminalization of drug use disorder, poverty, and racism,
HIV prevalence in criminallegal involved populations (CLIP) is higher than in people who …